Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kindstar Globalgene Technology's earnings before interest and taxes (EBIT) for the
six
months ended in Dec. 2025 was HK$-3 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-28 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Kindstar Globalgene Technology's annualizedROC % for the quarter that ended in Dec. 2025 was -3.13%.
Kindstar Globalgene Technology's annualizedROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -0.72%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
Kindstar Globalgene Technology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 12.37%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kindstar Globalgene Technology EBIT Related Terms
Kindstar Globalgene Technology EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Kindstar Globalgene Technology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kindstar Globalgene Technology EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Kindstar Globalgene Technology's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Kindstar Globalgene Technology's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-28 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kindstar Globalgene Technology (HKSE:09960) has a EBIT of HK$-28 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Kindstar Globalgene Technology.
Is Kindstar Globalgene Technology's EBIT too high?
Kindstar Globalgene Technology's current EBIT is HK$-28 Mil. Overall, Kindstar Globalgene Technology has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Kindstar Globalgene Technology's EBIT compare to TMO and DHR?
Kindstar Globalgene Technology's EBIT of HK$-28 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Diagnostics & Research company?
A good EBIT depends on the Medical Diagnostics & Research industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Kindstar Globalgene Technology. Kindstar Globalgene Technology's current EBIT is HK$-28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kindstar Globalgene Technology stock overvalued right now?
Based on GuruFocus' analysis, Kindstar Globalgene Technology (HKSE:09960) is currently considered Fairly Valued. The stock's GF Value™ is HK$1.06, compared to a current price of HK$1.00 — trading 5.7% below its estimated fair value. The current EBIT is HK$-28 Mil. Kindstar Globalgene Technology's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Kindstar Globalgene Technology (HKSE:09960), the current EBIT is HK$-28 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kindstar Globalgene Technology (HKSE:09960) Overvalued in 2026?
Based on GuruFocus' analysis, Kindstar Globalgene Technology stock appears to be undervalued.
The current stock price of HK$1.00 is trading 5.7% below its estimated GF Value™ of HK$1.06.
GuruFocus considers Kindstar Globalgene Technology to be Fairly Valued.
Key valuation signals for HKSE:09960:
EBIT: HK$-28 Mil
GF Value™: HK$1.06 vs. price of HK$1.00 (5.7% below fair value)
No single metric tells the full story. See the HKSE:09960 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kindstar Globalgene Technology Inc is engaged in the provision of clinical testing services in China. It operates in nine segments: Hematology testing segment includes testing services related to blood diseases; Genetic diseases and rare diseases segment includes testing services for rare diseases; Infectious diseases segment includes testing services from the infection department; Oncology segment includes testing related to oncology diseases; Neurology segment includes testing services related to neurological diseases undertaken by the Group; Maternity-related diseases segment includes testing services related to maternity; Routine testing segment conducts routine tests for the doctors daily diagnoses; CROs & R&D project segment includes research & develop services; & others segment.
69GF Score
Get the complete analysis for HKSE:09960
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:09960 has been successfully added to your 
